Inactive Instrument

Highlights Ibio Inc Nyse

Equities

US4510331048

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

IBio, Inc. and AstralBio, Inc. Announce Transformative AI Drug Discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases	Mar. 27	CI
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka	Feb. 26	DJ
Otsuka Pharmaceutical Co., Ltd. completed the acquisition of Preclinical PD-1 Agonist Antibody Program of iBio, Inc..	Feb. 24	CI
IBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 09	CI
Reverse Split: 1 of 20	Nov. 28	FA
North American Morning Briefing : November Rally Pauses Ahead of This Week's PCE Report	Nov. 28	DJ
IBio Board Approves 20-to-1 Reverse Split of Common Stock Effective Nov. 29; Shares Sink 11% After Hours	Nov. 27	MT
IBio, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
IBio, Inc. Announces Expansion of its AI-Powered Technology Stack with Launch of ShieldTx	Nov. 01	CI
IBio, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-27	CI
IBio, Inc. Reports Triple Milestone in Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development	23-08-14	CI
IBio Teams Up With National Institute of Allergy and Infectious Diseases to Work on Lassa Fever Vaccine Development	23-06-13	MT
IBio, Inc. Enters into Research Collaboration with the National Institute of Allergy and Infectious Diseases	23-06-12	CI
IBio, Inc. Announces the Expansion of Its AI-Powered Technology Stack with the Launch of EngageTx	23-06-06	CI
IBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-15	CI
North American Morning Briefing : Stock Futures Retreat on Rate Hike Worries	23-02-17	DJ
IBio Announces MUC16 as its Latest Immune-Oncology Target Program	23-02-16	CI
IBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-14	CI
IBio, Inc. to Showcase the RubrYc Discovery Engine During Poster Presentations At Antibody Engineering & Therapeutics Conference 2022	22-12-05	CI
IBio, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ibio Inc Nyse

Equities

US4510331048

Highlights

Filters